Visit f Mr.Karol M Rogawski FRCS Urol Consultant Urologist
The News Review:
- Visit f Mr.Karol M Rogawski FRCS Urol Consultant Urologist
- New prostate cancer treatment drawing US patients doctors to Mexico
- Biotech firm with Israeli vice chair sold to J&J for $1b
- BCM cell biologist receives top American Urological Association honor
- Hospital fundraiser benefits urology patients
- Investment exec urologist spend $1.55M in Winnetka
- Advanced Prostate Cancer Deadlier in Younger Men
Visit f Mr.Karol M Rogawski FRCS Urol Consultant Urologist
The Islander
2009 (Current Article)Dear Dr. Alex Wonner I would like to take this opportunity to thank you and the Ascension Island Government for an invitation to provide urology consultations for the patients under your care.
New prostate cancer treatment drawing US patients doctors to Mexico
Austin American-Statesman
I’ve got cancer; let’s do something. John Ward an assistant professor of urology at the University of Texas M. Anderson Cancer Center in Houston said he is a proponent of the new technology and is doing clinical trials on a rival device from a French company called EDAP. He expects to test International HIFU’s equipment soon but he said he is concerned about patients being seduced “with the flash of technology” and the promise of better outcomes while the trials are under way. Ward said patients should consider enrolling in clinical trials in the United States rather than paying out of pocket to leave the country for procedures.
Related from Fathernickthomas: Personal Health: News and Notes
Biotech firm with Israeli vice chair sold to J&J for $1b
Ha'aretz
Arie Belldegrun an Israeli expatriate joined Cougar Biotechnology Inc. in December 2003 as vice chairman of the board of directors and chairman of the scientific advisory board. He is chief of the Division of Urologic ncology and holds the Roy and Carol Doumani Chair in Urologic ncology at the David Geffen School of Medicine at the University of California Los Angeles. He is also the founder of Agensys Inc. a privately held biotechnology company focused on the development of fully human monoclonal antibodies to treat solid tumor cancers based on Agensys’ proprietary targets. Belldegrun served as founding chairman of Agensys from 1997-2002 and currently serves on the company’s board of directors and as a consultant. He completed his medical degree at the Hebrew University-Hadassah Medical School in Jerusalem his postgraduate fellowship at the Weizmann Institute of Science and his residency in urology at Harvard Medical School.
BCM cell biologist receives top American Urological Association honor
BCM News
David Rowley received the. Lattimer Award at the organization’s recent annual meeting in Chicago.
Hospital fundraiser benefits urology patients
Victoria News
It will be used to help diagnose and treat people with kidney bladder and prostate problems. About 5200 procedures are completed annually on urology operating tables at Royal Jubilee and Victoria General hospitals. Each new table costs $330000. To make a donation please contact the foundation at 250-414-6688 or visit www.
Investment exec urologist spend $1.55M in Winnetka
Blockshopper
Macejko specializes in urology at Northshore Memorial Hospital in Evanston. from Emory University School of Medicine in 2001 and completed her fellowship in endourology at Northwestern University Feinberg School of Medicine. There were 127 home sales in.
Advanced Prostate Cancer Deadlier in Younger Men
Atlanta Journal Constitution
Brawley chief medical officer of the American Cancer Society. “Men with high-grade tumors are less likely to benefit from screening” Brawley said. But the results drew exactly the opposite reaction from Dr. Stephen Freedland an associate professor of urology and pathology at Duke University. “Really young men those 35 to 44 have worse cancers” Freedland said. “This is not a group of men where we typically screen for prostate cancer. The percentage of metastatic disease is higher than for any other group.
Written by admin on May 24th, 2009 with
no comments.
Read more articles on News.